GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes
Authors:
- 22 December 2011
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 14 (3) , 271-278
Abstract
Aim: Free fatty acids act as signalling molecules for modulating insulin secretion, and their insulinotropic effects are glucose‐dependent and mediated through G protein‐coupled receptor 40 (GPR40). This mechanism is a potential target for new treatments for managing diabetes. In this study, we present the first clinical data for TAK‐875, a novel highly selective, orally bioavailable GPR40 agonist, in Japanese patients with type 2 diabetes insufficiently controlled by diet or exercise therapy. Methods: This was an exploratory phase II, multicentre, randomized, double‐blind, parallel group study comparing the efficacy and tolerability of TAK‐875 100 and 400 mg, and placebo, all administered once daily for 2 weeks. Results: After 2 weeks of treatment, TAK‐875 produced marked glucose lowering effects in a 75 g oral glucose tolerance test (OGTT) as evidenced by mean ± SE intergroup differences in plasma glucose AUC 0–3 h of −12.98 ± 1.48 (p < 0.0001) and −8.12 ± 1.49 mmol·h/l (p < 0.0001), for TAK‐875 400 mg vs. placebo and TAK‐875 100 mg vs. placebo, respectively, and 2 h plasma glucose [−4.95 ± 0.71 (p < 0.0001) and −3.21 ± 0.71 mmol/l (p < 0.0001), respectively]. This was accompanied by a significant increase in insulin AUC 0–3 h [34.68 ± 12.16 (p < 0.01) and 31.49 ± 12.20 (p < 0 · 05) µIU·h/ml, respectively]. Improvement in glycaemic profile was mirrored by a significant change in fasting plasma glucose [−2.37 ± 0·27 (p < 0.0001) and −1.88 ± 0.27 mmol/l (p < 0.0001), respectively]. No cases of hypoglycaemia were observed despite the significant reduction in plasma glucose. Conclusions: These exploratory findings provide evidence of the glucose‐dependent insulinotropic potential of the GPR40 agonist TAK‐875, and the promising clinical changes support future longer term clinical investigation.Keywords
This publication has 26 references indexed in Scilit:
- Overexpression of GPR40 in Pancreatic β-Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic MiceDiabetes, 2009
- The Fatty Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat FeedingDiabetes, 2008
- Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin SecretionDiabetes, 2008
- Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in MiceDiabetes, 2008
- Fatty acid receptors as new therapeutic targets for diabetesExpert Opinion on Therapeutic Targets, 2007
- GPR40 is expressed in glucagon producing cells and affects glucagon secretionBiochemical and Biophysical Research Communications, 2007
- The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyDiabetes, 2006
- Oleic acid interacts with GPR40 to induce Ca2+signaling in rat islet β-cells: mediation by PLC and L-type Ca2+channel and link to insulin releaseAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Role of GPR40 in fatty acid action on the β cell line INS-1EBiochemical and Biophysical Research Communications, 2005
- Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40Nature, 2003